A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 5, 2019

Primary Completion Date

March 15, 2022

Study Completion Date

March 15, 2022

Conditions
Chronic HBV Infection
Interventions
DRUG

HH-003 injection

HH-003 injection is administrated via I.V. infusion

DRUG

Placebo

Placebo is administrated via I.V. infusion

Trial Locations (11)

100015

Beijing Ditan Hospital,Capital Medical University, Beijing

100050

Beijing Friendship Hospital,Capital Medical University, Beijing

100069

Beijing Youan Hospital,Capital Medical University, Beijing

130021

The First Hospital of Jilin University, Changchun

133000

Yanbian University Hospital(Yanbian Hospital), Yanji

250102

Shandong Public Health Clinical Center, Jinan

310003

The First Affiliated Hospital,Zhejiang University School Of Medicine, Hangzhou

350025

Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou

450000

The First Affiliated Hospital Of Zhengzhou University, Zhengzhou

450006

Henan Infectious Disease Hospital(The Sixth Peoples Hospital Of Zhengzhou), Zhengzhou

730000

The First Hospital of Lanzhou University, Lanzhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05542979 - A Study to Evaluate the Safety, Tolerability of HH-003 Injection in Participants With Chronic Hepatitis B Virus Infection | Biotech Hunter | Biotech Hunter